Synstatin Therapy for Multiple Myeloma

多发性骨髓瘤的合成他汀治疗

基本信息

  • 批准号:
    8010929
  • 负责人:
  • 金额:
    $ 38.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-01-01 至 2014-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Multiple myeloma is the second most prevalent hematologic malignancy and accounts for over 10% of all hematologic cancers in the United States. It is estimated that over 16,500 new cases of myeloma are diagnosed and over 11,000 die from this disease each year. Although progress has been made in treatment over the last decade, the overall outlook for patients is grim. Multiple myeloma is a disease in which malignant plasma cells invade to populate and form tumors within the bone marrow. Their interactions with the tumor microenvironment lead to the release of cytokines that support myeloma cell proliferation, stimulate angiogenesis that supports myeloma cell growth and metastasis, and trigger bone lytic disease by over-stimulating differentiation of osteoclasts and their ensuing destruction of the bone. We have discovered a central mechanism in all of these processes that involves four effectors, each known to have a role in myeloma formation and progression - namely, the matrix receptor syndecan-1 (Sdc1), the av¿3 and av¿3 integrins, the insulin-like growth factor-1 receptor, and heparanase. The central mechanism is activation of a signaling complex comprised of Sdc1, the two integrins and the IGF1R when Sdc1 is activated by cleavage of its heparan sulfate chains by heparanase. Importantly, this mechanism is blocked by a peptide (called synstatin (SSTN)) that targets the active site on syndecan-1. This proposal will examine the mechanism by which Sdc1 is activated by heparanase on the myeloma cells, leading to tumorigenesis of the myeloma and heightened activation of vascular endothelial cells and osteoclast progenitors in the tumor microenvironment. Next, we will test the efficacy of SSTN as an inhibitor of this mechanism on the tumor cells and the cells in their microenvironment. The benefit of this work is likely to be new and effective treatments for multiple myeloma and other cancers. PUBLIC HEALTH RELEVANCE: Multiple myeloma is the second most prevalent hematologic malignancy. A novel mechanism, based on the matrix receptor syndecan-1 that is highly expressed in multiple myeloma, will be targeted by a new therapeutic called synstatin. Synstatin will be tested for its efficacy on the myeloma tumor and on the tumor microenvironment.
描述(申请人提供):多发性骨髓瘤是第二位最常见的血液系统恶性肿瘤,占美国所有血液系统癌症的10%以上。据估计,每年有超过16,500例新的骨髓瘤病例被诊断出来,超过11,000人死于这种疾病。尽管过去十年在治疗方面取得了进展,但患者的总体前景依然严峻。多发性骨髓瘤是一种恶性浆细胞侵入骨髓并在骨髓内形成肿瘤的疾病。它们与肿瘤微环境的相互作用导致支持骨髓瘤细胞增殖的细胞因子的释放,刺激支持骨髓瘤细胞生长和转移的血管生成,并通过过度刺激破骨细胞的分化及其随之而来的骨破坏而引发溶骨性疾病。我们已经发现了所有这些过程中的一个中心机制,涉及四个已知在骨髓瘤形成和进展中发挥作用的效应器--即基质受体Syndecan-1(SDc1)、av?3和av?3整合素、胰岛素样生长因子-1受体和乙酰肝素酶。其核心机制是当Sdc1被乙酰肝素酶切割其硫酸乙酰肝素链而激活时,由Sdc1、两个整合素和IGF1R组成的信号复合体被激活。重要的是,这种机制被一种被称为Synstatin(SSTN)的多肽所阻断,这种多肽针对Syndecan-1上的活性部位。这项建议将研究Sdc1被骨髓瘤细胞上的肝素酶激活,导致骨髓瘤发生和肿瘤微环境中血管内皮细胞和破骨细胞前体细胞激活的机制。接下来,我们将测试SSTN作为这一机制的抑制剂对肿瘤细胞及其微环境中的细胞的有效性。这项工作的好处可能是多发性骨髓瘤和其他癌症的新的有效治疗方法。 公共卫生相关性:多发性骨髓瘤是第二大最常见的血液系统恶性肿瘤。一种新的机制,基于多发性骨髓瘤中高表达的基质受体Syndecan-1,将成为一种名为Synstatin的新疗法的靶点。将测试Synstatin对骨髓瘤和肿瘤微环境的疗效。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(10)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ALAN C RAPRAEGER其他文献

ALAN C RAPRAEGER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ALAN C RAPRAEGER', 18)}}的其他基金

A kinase-independent role for EGFR in p38MAPK suppression and S-phase progression in head and neck cancer
EGFR 在头颈癌 p38MAPK 抑制和 S 期进展中的激酶独立作用
  • 批准号:
    9885259
  • 财政年份:
    2020
  • 资助金额:
    $ 38.91万
  • 项目类别:
A kinase-independent role for EGFR in p38MAPK suppression and S-phase progression in head and neck cancer
EGFR 在头颈癌 p38MAPK 抑制和 S 期进展中的激酶独立作用
  • 批准号:
    10392360
  • 财政年份:
    2020
  • 资助金额:
    $ 38.91万
  • 项目类别:
Syndecan-1 (CD138) and its synstatins: targeting invasion, survival and angiogenesis in myeloma
Syndecan-1 (CD138) 及其 Synstatins:靶向骨髓瘤的侵袭、存活和血管生成
  • 批准号:
    9383657
  • 财政年份:
    2017
  • 资助金额:
    $ 38.91万
  • 项目类别:
Syndecan-1 (CD138) and its synstatins: targeting invasion, survival and angiogenesis in myeloma
Syndecan-1 (CD138) 及其 Synstatins:靶向骨髓瘤的侵袭、存活和血管生成
  • 批准号:
    10208798
  • 财政年份:
    2017
  • 资助金额:
    $ 38.91万
  • 项目类别:
Signaling role of syndecans in HER2+ and triple negative breast cancer
Syndecans 在 HER2 和三阴性乳腺癌中的信号作用
  • 批准号:
    8777946
  • 财政年份:
    2013
  • 资助金额:
    $ 38.91万
  • 项目类别:
Signaling role of syndecans in HER2+ and triple negative breast cancer
Syndecans 在 HER2 和三阴性乳腺癌中的信号作用
  • 批准号:
    8439629
  • 财政年份:
    2013
  • 资助金额:
    $ 38.91万
  • 项目类别:
Signaling role of syndecans in HER2+ and triple negative breast cancer
Syndecans 在 HER2 和三阴性乳腺癌中的信号作用
  • 批准号:
    8987547
  • 财政年份:
    2013
  • 资助金额:
    $ 38.91万
  • 项目类别:
Signaling role of syndecans in HER2+ and triple negative breast cancer
Syndecans 在 HER2 和三阴性乳腺癌中的信号作用
  • 批准号:
    8601294
  • 财政年份:
    2013
  • 资助金额:
    $ 38.91万
  • 项目类别:
Synstatin Therapy for Multiple Myeloma
多发性骨髓瘤的合成他汀治疗
  • 批准号:
    8403534
  • 财政年份:
    2010
  • 资助金额:
    $ 38.91万
  • 项目类别:
Synstatin Therapy for Multiple Myeloma
多发性骨髓瘤的合成他汀治疗
  • 批准号:
    8190334
  • 财政年份:
    2010
  • 资助金额:
    $ 38.91万
  • 项目类别:

相似海外基金

Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
  • 批准号:
    2334970
  • 财政年份:
    2024
  • 资助金额:
    $ 38.91万
  • 项目类别:
    Standard Grant
NSF-BSF: Towards a Molecular Understanding of Dynamic Active Sites in Advanced Alkaline Water Oxidation Catalysts
NSF-BSF:高级碱性水氧化催化剂动态活性位点的分子理解
  • 批准号:
    2400195
  • 财政年份:
    2024
  • 资助金额:
    $ 38.91万
  • 项目类别:
    Standard Grant
Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
  • 批准号:
    2334969
  • 财政年份:
    2024
  • 资助金额:
    $ 38.91万
  • 项目类别:
    Standard Grant
Mechanochemical synthesis of nanocarbon and design of active sites for oxygen reducton/evolution reactions
纳米碳的机械化学合成和氧还原/演化反应活性位点的设计
  • 批准号:
    23K04919
  • 财政年份:
    2023
  • 资助金额:
    $ 38.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Creation of porous inorganic frameworks with controlled structure of metal active sites by the building block method.
通过积木法创建具有金属活性位点受控结构的多孔无机框架。
  • 批准号:
    22KJ2957
  • 财政年份:
    2023
  • 资助金额:
    $ 38.91万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Catalysis of Juxaposed Active Sites Created in Nanospaces and Their Applications
纳米空间中并置活性位点的催化及其应用
  • 批准号:
    23K04494
  • 财政年份:
    2023
  • 资助金额:
    $ 38.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Generation of carbon active sites by modifying the oxygen containing functional groups and structures of carbons for utilizing to various catalytic reactions.
通过修饰碳的含氧官能团和结构来产生碳活性位点,用于各种催化反应。
  • 批准号:
    23K13831
  • 财政年份:
    2023
  • 资助金额:
    $ 38.91万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
CAREER: CAS: Understanding the Chemistry of Palladium and Silyl Compounds to Design Catalyst Active Sites
职业:CAS:了解钯和甲硅烷基化合物的化学性质以设计催化剂活性位点
  • 批准号:
    2238379
  • 财政年份:
    2023
  • 资助金额:
    $ 38.91万
  • 项目类别:
    Continuing Grant
CAS: Collaborative Research: Tailoring the Distribution of Transient vs. Dynamic Active Sites in Solid-Acid Catalysts and Their Impacts on Chemical Conversions
CAS:合作研究:定制固体酸催化剂中瞬时活性位点与动态活性位点的分布及其对化学转化的影响
  • 批准号:
    2154399
  • 财政年份:
    2022
  • 资助金额:
    $ 38.91万
  • 项目类别:
    Standard Grant
Engineering of Active Sites in Heterogeneous Catalysts for Sustainable Chemical and Fuel Production.
用于可持续化学和燃料生产的多相催化剂活性位点工程。
  • 批准号:
    RGPIN-2019-06633
  • 财政年份:
    2022
  • 资助金额:
    $ 38.91万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了